Our group found that non-responders were significantly enriched for immunosuppressive phosphatase and tensin homolog (PTEN) mutations, while responders were more likely to have mitogen-activated protein kinase (MAPK) pathway aberrancies including protein tyrosine phosphatase non-receptor type 11 (PTPN11) and B rapidly accelerated fibrosarcoma (BRAF) mutations [125]. The gene discussed is PTEN; the disease is fibrosarcoma.